Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828094 | 0.84 | POLB (0.45) | POLBL3MBTL1MAPTNPSR1NQO2 | |
| SCHEMBL31554539 | 0.79 | POLB (0.45) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL30103969 | 0.79 | POLB (0.50) | POLBL3MBTL1MAPTNPSR1NQO2 | |
| SCHEMBL14478701 | 0.78 | NQO2 (0.37) | POLBL3MBTL1MAPTNPSR1NQO2 | |
| SCHEMBL31149382 | 0.77 | CA2 (0.30) | MAPTNPSR1NQO2ALDH1A1PRNP | |
| SCHEMBL19407727 | 0.76 | POLB (0.38) | POLBL3MBTL1MAPTNPSR1NQO2 | |
| SCHEMBL25384198 | 0.75 | TAAR1 (0.39) | MAPTHTR2AHTR2CTAAR1ALDH1A1 | |
| SCHEMBL21436972 | 0.75 | PDE4A (0.48) | HTR2AHTR2CTAAR1ALDH1A1PGK1 | |
| SCHEMBL22962870 | 0.75 | CCNA2 (0.33) | MAPTNPSR1PRKDCLCKFYN | |
| SCHEMBL21437043 | 0.75 | PRKDC (0.55) | L3MBTL1MAPTPRKDCALDH1A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433258-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| WO-2017165255-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017160569-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-9573938-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2014043252-A2 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014043252-A2 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-2542077-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| WO-2011109261-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109261-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-0199324-B1 | NEW 2,5-DIARYL TETRYHYDROFURANS AND ANALOGS THEREOF AS PAF ANTAGONISTS | MERCK & CO. INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, P4HA1 | POLB 1601/4885L3MBTL1 4001/4885MAPT 4512/4885 |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | POLB 1004/4885L3MBTL1 1517/4885MAPT 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.